2005 Drug Development Vaccines 
STAT
DECEMBER 13, 2024
Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short of goals set by the United Nations and most of the increase came from just two organizations, according to a new report.
pharmaphorum
OCTOBER 12, 2022
“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 18, 2020
However, it withdrew its neuropharmacological drug, Zelmid, which was an SSRI, due to concerns over side effects only a year after it was introduced in 1982. In 1990, the US Food and Drug Administration (FDA) requested Astra to change Losec’s brand name to Prilosec, to avoid confusion with Sanofi-Aventis’ diuretic, Lasix (furosemide).
Pharmaceutical Technology
JULY 23, 2008
It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.
Express Pharma
JULY 10, 2024
India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million. Today, it is a key player in the global pharma landscape.
Pharmaceutical Technology
OCTOBER 28, 2022
Quality by design (QbD) is a concept introduced into the pharmaceutical regulatory lexicon in 2005. It aims to ensure the quality of medicines by employing statistical, analytical, and risk-management methodology in the design, development, and manufacturing processes of medicines.
PharmaShots
JANUARY 31, 2023
Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. Funding Value: $7M Founded Year: 2005 No. The company bagged its $6.3M IPO in Jun’22 offering shares at $4.25/unit. of Shares: 1.2M of Shares: 3.7M
Expert insights. Personalized for you.
260 
Let's personalize your content